Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life
Simone Benhamou,
Julia Bonastre,
Bijan Ghaleh,
Hélène Blanché,
Pascal Eschwege,
Arnauld Villers,
Arnaud Méjean,
François Radvanyi,
Xavier Rébillard,
Yves Allory,
Thierry Lebret,
Aldéric Fraslin,
Yann Neuzillet,
Stéphane Droupy,
Dimitri Vordos,
Laurent Guy,
Marc Schneider,
Patrick Coloby,
Jean Lacoste,
Jacques Lacoste,
Jean-Luc Descotes,
Guillaume Loison,
Odette Mariani,
Anthony Mangin,
Nanor Sirab,
Karine Groussard
Affiliations
Simone Benhamou
27INSERM U 946, Paris, France
Julia Bonastre
3Gustave Roussy, Service de Biostatistique et d`Epidemiologie, Villejuif, France
Bijan Ghaleh
9AP-HP, Hôpital Henri-Mondor, Plateforme de Ressources Biologiques, Créteil, France
Hélène Blanché
6Fondation Jean Dausset-CEPH, Paris, France
Pascal Eschwege
Service d`Urologie, CHU Bradois, Vandoeuvre-Lès-Nancy, France
Arnauld Villers
5 Department of Urology, CHU Lille, University Lille Nord de France, Lille, France
Arnaud Méjean
Urology, Hopital Europeen Georges Pompidou, Paris, France
François Radvanyi
Institut Curie, Centre de recherche, Paris, France
Xavier Rébillard
2Service Urologie, Clinique Beau Soleil, Montpellier, Occitanie, France
Yves Allory
Department of Pathology, Université Paris-Saclay, Institut Curie, Paris, France
Thierry Lebret
Urology, Hôpital Foch, Suresnes, France
Aldéric Fraslin
Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
Yann Neuzillet
Urology, Hôpital Foch, Suresnes, France
Stéphane Droupy
Urology, Centre Hospitalier Universitaire de Nimes, Nimes, France
Dimitri Vordos
Clinical Investigation Center 1430, INSERM, Créteil, France
Laurent Guy
Urology, University Hospital Centre Gabriel Montpied, Clermont-Ferrand, France
Marc Schneider
Urology, Hopitaux Civils de Colmar, Colmar, France
Patrick Coloby
Urology, University Hospital Center René Dubos, Cergy-Pontoise, France
Jean Lacoste
Urology, Private Hospital of Provence, Aix-en-Provence, France
Jacques Lacoste
Urology, Atlantis Clinic, Saint-Herblain, France
Jean-Luc Descotes
Urology, CHU Grenoble Alpes, Grenoble, France
Guillaume Loison
Urology, la Croix du Sud Clinic, Quint Fonsegrives, France
Odette Mariani
Biological Resources Center, Curie Institute Hospital Group, Paris, France
Anthony Mangin
Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
Purpose Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.Participants COBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up.Findings to date We describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy.Future plans COBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making.